BillionToOne's core innovation—adding known synthetic DNA before PCR amplification to quantify and subtract noise—transforms the needle-in-haystack detection of rare cell-free DNA (fetal or…

By starting with prenatal testing (lower regulatory burden, immediate revenue), BillionToOne funds development of late-stage cancer MRD test, then early-stage MRD, and ultimately annual pop…